Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth | Fungal Infections | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Sobel  JD.  Vulvovaginal candidosis .  Lancet. 2007;369(9577):1961-1971.PubMedGoogle ScholarCrossref
Cotch  MF, Hillier  SL, Gibbs  RS, Eschenbach  DA; Vaginal Infections and Prematurity Study Group.  Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy .  Am J Obstet Gynecol. 1998;178(2):374-380.PubMedGoogle ScholarCrossref
Eckert  LO.  Clinical practice: acute vulvovaginitis .  N Engl J Med. 2006;355(12):1244-1252.PubMedGoogle ScholarCrossref
Tooley  PJ.  Patient and doctor preferences in the treatment of vaginal candidosis .  Practitioner. 1985;229(1405):655-660.PubMedGoogle Scholar
Aleck  KA, Bartley  DL.  Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient .  Am J Med Genet. 1997;72(3):253-256.PubMedGoogle ScholarCrossref
Lee  BE, Feinberg  M, Abraham  JJ, Murthy  AR.  Congenital malformations in an infant born to a woman treated with fluconazole .  Pediatr Infect Dis J. 1992;11(12):1062-1064.PubMedGoogle ScholarCrossref
Lopez-Rangel  E, Van Allen  MI.  Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype .  Birth Defects Res A Clin Mol Teratol. 2005;73(11):919-923.PubMedGoogle ScholarCrossref
Pursley  TJ, Blomquist  IK, Abraham  J, Andersen  HF, Bartley  JA.  Fluconazole-induced congenital anomalies in three infants .  Clin Infect Dis. 1996;22(2):336-340.PubMedGoogle ScholarCrossref
Inman  W, Pearce  G, Wilton  L.  Safety of fluconazole in the treatment of vaginal candidiasis: a prescription-event monitoring study, with special reference to the outcome of pregnancy .  Eur J Clin Pharmacol. 1994;46(2):115-118.PubMedGoogle ScholarCrossref
Jick  SS.  Pregnancy outcomes after maternal exposure to fluconazole .  Pharmacotherapy. 1999;19(2):221-222.PubMedGoogle ScholarCrossref
Mastroiacovo  P, Mazzone  T, Botto  LD,  et al.  Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole .  Am J Obstet Gynecol. 1996;175(6):1645-1650.PubMedGoogle ScholarCrossref
Mølgaard-Nielsen  D, Pasternak  B, Hviid  A.  Use of oral fluconazole during pregnancy and the risk of birth defects .  N Engl J Med. 2013;369(9):830-839.PubMedGoogle ScholarCrossref
Nørgaard  M, Pedersen  L, Gislum  M,  et al.  Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study .  J Antimicrob Chemother. 2008;62(1):172-176.PubMedGoogle ScholarCrossref
Wilton  LV, Pearce  GL, Martin  RM, Mackay  FJ, Mann  RD.  The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England .  Br J Obstet Gynaecol. 1998;105(8):882-889.PubMedGoogle ScholarCrossref
Knudsen  LB, Olsen  J.  The Danish Medical Birth Registry .  Dan Med Bull. 1998;45(3):320-323.PubMedGoogle Scholar
Jørgensen  FS.  Ultrasonography of pregnant women in Denmark 1999-2000: description of the development since 1980-1990 [in Danish] .  Ugeskr Laeger. 2003;165(46):4409-4415.PubMedGoogle Scholar
Lynge  E, Sandegaard  JL, Rebolj  M.  The Danish National Patient Register .  Scand J Public Health. 2011;39(7)(suppl):30-33.PubMedGoogle ScholarCrossref
Kildemoes  HW, Sørensen  HT, Hallas  J.  The Danish National Prescription Registry .  Scand J Public Health. 2011;39(7)(suppl):38-41.PubMedGoogle ScholarCrossref
Pedersen  CB.  The Danish Civil Registration System .  Scand J Public Health. 2011;39(7)(suppl):22-25.PubMedGoogle ScholarCrossref
Austin  PC.  Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations .  Biom J. 2009;51(1):171-184.PubMedGoogle ScholarCrossref
Rassen  JA, Shelat  AA, Myers  J, Glynn  RJ, Rothman  KJ, Schneeweiss  S.  One-to-many propensity score matching in cohort studies .  Pharmacoepidemiol Drug Saf. 2012;21(2)(suppl 2):69-80.PubMedGoogle ScholarCrossref
The Danish Health and Medicines Authority. The Birth Registry 2004 [in Danish]. Accessed March 24, 2015.
Daneshmend  TK.  Systemic absorption of miconazole from the vagina .  J Antimicrob Chemother. 1986;18(4):507-511.PubMedGoogle ScholarCrossref
Ritter  W, Patzschke  K, Krause  U, Stettendorf  S.  Pharmacokinetic fundamentals of vaginal treatment with clotrimazole .  Chemotherapy. 1982;28(1)(suppl 1):37-42.PubMedGoogle ScholarCrossref
Christensen  B.  Which antibiotics are appropriate for treating bacteriuria in pregnancy?  J Antimicrob Chemother. 2000;46(1)(suppl A):29-34. PubMedGoogle ScholarCrossref
Buhimschi  CS, Weiner  CP.  Medications in pregnancy and lactation: part 1: teratology .  Obstet Gynecol. 2009;113(1):166-188.PubMedGoogle ScholarCrossref
Pfizer. Diflucan [product information]. Accessed Marts 24, 2015.
Marotta  F, Tiboni  GM.  Molecular aspects of azoles-induced teratogenesis .  Expert Opin Drug Metab Toxicol. 2010;6(4):461-482.PubMedGoogle ScholarCrossref
Xu  R, Luo  Y, Chambers  C.  Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models .  Pharmacoepidemiol Drug Saf. 2012;21(8):844-850.PubMedGoogle ScholarCrossref
Ho  CY, Aterman  K.  Infection of the fetus by Candida in a spontaneous abortion .  Am J Obstet Gynecol. 1970;106(5):705-710.PubMedGoogle Scholar
Hood  IC, Desa  DJ, Whyte  RK.  The inflammatory response in candidal chorioamnionitis .  Hum Pathol. 1983;14(11):984-990.PubMedGoogle ScholarCrossref
Meizoso  T, Rivera  T, Fernández-Aceñero  MJ, Mestre  MJ, Garrido  M, Garaulet  C.  Intrauterine candidiasis: report of four cases .  Arch Gynecol Obstet. 2008;278(2):173-176.PubMedGoogle ScholarCrossref
Roqué  H, Abdelhak  Y, Young  BK.  Intra amniotic candidiasis: case report and meta-analysis of 54 cases .  J Perinat Med. 1999;27(4):253-262.PubMedGoogle Scholar
Whyte  RK, Hussain  Z, deSa  D.  Antenatal infections with Candida species .  Arch Dis Child. 1982;57(7):528-535.PubMedGoogle ScholarCrossref
Goldenberg  RL, Hauth  JC, Andrews  WW.  Intrauterine infection and preterm delivery .  N Engl J Med. 2000;342(20):1500-1507.PubMedGoogle ScholarCrossref
Hay  PE.  Bacterial vaginosis and miscarriage .  Curr Opin Infect Dis. 2004;17(1):41-44.PubMedGoogle ScholarCrossref
Michels  TC, Tiu  AY.  Second trimester pregnancy loss .  Am Fam Physician. 2007;76(9):1341-1346.PubMedGoogle Scholar
Lohse  SR, Farkas  DK, Lohse  N,  et al.  Validation of spontaneous abortion diagnoses in the Danish National Registry of Patients .  Clin Epidemiol. 2010;2:247-250.PubMedGoogle ScholarCrossref
Wilcox  AJ, Weinberg  CR, O’Connor  JF,  et al.  Incidence of early loss of pregnancy .  N Engl J Med. 1988;319(4):189-194.PubMedGoogle ScholarCrossref
Original Investigation
January 5, 2016

Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth

Author Affiliations
  • 1Department of Epidemiology Research, Statens Serum Institut, Copenhagen S, Denmark
JAMA. 2016;315(1):58-67. doi:10.1001/jama.2015.17844

Importance  Vaginal candidiasis is common during pregnancy. Although intravaginal formulations of topical azole antifungals are first-line treatment for pregnant women, oral fluconazole is often used despite limited safety information.

Objective  To study the association between oral fluconazole exposure during pregnancy and the risk of spontaneous abortion and stillbirth.

Design, Setting, and Participants  Nationwide register-based cohort study in Denmark, 1997-2013. From a cohort of 1 405 663 pregnancies, oral fluconazole–exposed pregnancies were compared with up to 4 unexposed pregnancies matched on propensity score, maternal age, calendar year, and gestational age (based on gestational age at first day of treatment with eligible controls surviving through this date). To test for confounding by indication, pregnancies exposed to intravaginal formulations of topical azoles were used as an additional comparator group.

Exposures  Filled prescriptions for oral fluconazole were obtained from the National Prescription Register.

Main Outcomes and Measures  Hazard ratios (HRs) for spontaneous abortion and stillbirth, estimated using proportional hazards regression.

Results  Among 3315 women exposed to oral fluconazole from 7 through 22 weeks’ gestation, 147 experienced a spontaneous abortion, compared with 563 among 13 246 unexposed matched women. There was a significantly increased risk of spontaneous abortion associated with fluconazole exposure (HR, 1.48; 95% CI, 1.23-1.77). Among 5382 women exposed to fluconazole from gestational week 7 to birth, 21 experienced a stillbirth, compared with 77 among 21 506 unexposed matched women. There was no significant association between fluconazole exposure and stillbirth (HR, 1.32 [95% CI, 0.82-2.14]). Using topical azole exposure as the comparison, 130 of 2823 women exposed to fluconazole vs 118 of 2823 exposed to topical azoles had a spontaneous abortion (HR, 1.62 [95% CI, 1.26-2.07]); 20 of 4301 women exposed to fluconazole vs 22 of 4301 exposed to topical azoles had a stillbirth (HR, 1.18 [95% CI, 0.64-2.16]).

Conclusions and Relevance  In this nationwide cohort study in Denmark, use of oral fluconazole in pregnancy was associated with a statistically significant increased risk of spontaneous abortion compared with risk among unexposed women and women with topical azole exposure in pregnancy. Until more data on the association are available, cautious prescribing of fluconazole in pregnancy may be advisable. Although the risk of stillbirth was not significantly increased, this outcome should be investigated further.